Centurión D, Sánchez-López A, Ortiz M I, De Vries P, Saxena P R, Villalón C M
Departamento de Farmacología, CINVESTAV-I.P.N., México D.F.
Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):169-76. doi: 10.1007/s002100000277.
The vasoconstrictor effects of 5-hydroxytryptamine (5-HT) in the internal carotid bed of anaesthetised dogs with bilateral vagosympathectomy are mainly mediated by both 5-HT1B and 5-HT2 receptors. The blockade of this vasoconstrictor effect of 5-HT by the combined use of the antagonists, GR127935 (5-HT1B/1D) and ritanserin (5-HT2), unmasks a dose-dependent vasodilator effect of 5-HT, but not of sumatriptan. Therefore, the present study set out to analyse the pharmacological profile of this vasodilator 5-HT receptor in the internal carotid bed of vagosympathectomized dogs systematically pretreated with intravenous (i.v.) injections of GR127935 (30 microg/kg) and ritanserin (100 microg/kg). One-minute (1-min) intracarotid (i.c.) infusions of 5-HT (0.1-10 microg/min), 5-carboxamidotryptamine (5-CT; 0.01-0.3 microg/min), 5-methoxytryptamine (5-MeO-T; 1-100 microg/min) and acetylcholine (ACh; 0.003-0.1 microg/min) resulted in dose-dependent increases in internal carotid blood flow (without changes in blood pressure or heart rate) with a rank order of agonist potency of ACh > 5-CT >> 5-HT > or =5-MeO-T. The internal carotid vasodilator responses to 5-HT, 5-CT and 5-MeO-T, which remained unaffected after saline (0.03 ml/kg and 0.1 ml/kg, i.v.), were specifically and dose-dependently blocked by i.v. administration of lisuride (10 microg/kg and 30 microg/kg), clozapine (1000 microg/kg), mesulergine (300 microg/kg and 1000 microg/kg) and LY215840 (300 microg/kg and 1000 microg/kg) with the following apparent rank order of potency: lisuride >> mesulergine = LY215840 > or = clozapine. The above results suggest that the 5-HT receptor mediating internal carotid vasodilatation in vagosympathectomized dogs pretreated with GR127935 and ritanserin is operationally similar to other 5-HT7 receptors mediating vascular and non-vascular responses.
在双侧迷走神经交感神经切除的麻醉犬颈内动脉床中,5-羟色胺(5-HT)的血管收缩作用主要由5-HT1B和5-HT2受体介导。联合使用拮抗剂GR127935(5-HT1B/1D)和利坦色林(5-HT2)阻断5-HT的这种血管收缩作用后,可揭示5-HT(而非舒马曲坦)的剂量依赖性血管舒张作用。因此,本研究旨在系统分析经静脉注射GR127935(30微克/千克)和利坦色林(100微克/千克)预处理的双侧迷走神经交感神经切除犬颈内动脉床中这种血管舒张性5-HT受体的药理学特征。颈内动脉内1分钟输注5-HT(0.1 - 10微克/分钟)、5-羧酰胺色胺(5-CT;0.01 - 0.3微克/分钟)、5-甲氧基色胺(5-MeO-T;1 - 100微克/分钟)和乙酰胆碱(ACh;0.003 - 0.1微克/分钟)导致颈内动脉血流量呈剂量依赖性增加(血压和心率无变化),激动剂效力顺序为ACh > 5-CT >> 5-HT ≥5-MeO-T。颈内动脉对5-HT, 5-CT和5-MeO-T的血管舒张反应在静脉注射生理盐水(0.03毫升/千克和0.1毫升/千克)后不受影响,但静脉注射利舒脲(10微克/千克和30微克/千克)、氯氮平(1000微克/千克)、美舒麦角(300微克/千克和1000微克/千克)和LY215840(300微克/千克和1000微克/千克)可特异性且剂量依赖性地阻断,效力的表观顺序如下:利舒脲 >> 美舒麦角 = LY215840 ≥氯氮平。上述结果表明,在经GR127935和利坦色林预处理的双侧迷走神经交感神经切除犬中,介导颈内动脉血管舒张的5-HT受体在功能上与介导血管和非血管反应的其他5-HT7受体相似。